Related Experiment Videos
[Intrahepatic cholestasis in pregnancy]
L Bonessio1, A Ciardo, V Spina
1Università degli Studi di Roma La Sapienza 1. Istituto di Clinica Ostetrica e Ginecologica.
La Clinica Terapeutica
|July 1, 1996
Summary
Intrahepatic cholestasis of pregnancy (ICP) is a liver condition affecting pregnant women. S-adenosyl-L-methionine (SaMe) effectively improved liver enzymes and bile acids in a patient with ICP.
Area of Science:
- Hepatology
- Obstetrics
- Biochemistry
Background:
- Intrahepatic cholestasis of pregnancy (ICP) is a pregnancy-specific liver disorder.
- It typically occurs in the third trimester, characterized by pruritus and altered liver function tests.
- While maternal prognosis is generally good, ICP poses risks to fetal well-being, including distress and prematurity.
Observation:
- Maternal prognosis for ICP is generally favorable.
- However, ICP poses risks of fetal distress and preterm birth.
- This study focuses on a specific patient case treated with S-adenosyl-L-methionine (SaMe).
Findings:
- S-adenosyl-L-methionine (SaMe) therapy demonstrated efficacy in managing ICP.
- Treatment led to the improvement of altered biochemical parameters.
- Normalization of liver function tests was achieved prior to delivery.
Implications:
- SaMe represents a potential therapeutic option for Intrahepatic cholestasis of pregnancy.
- Further research may validate SaMe for improving maternal and fetal outcomes in ICP.
- This case highlights the potential benefits of SaMe in managing ICP biochemical abnormalities.